US Government as Represented by the Secretary of the Army

Jean A Setterstrom

John E Van Hamont

Robert H Reid

Elliot Jacob

Charles E McQueen

Thomas R Tice

F Donald Roberts

Phil Friden

Curt Thies

Edgar C Boedeker

Frederick J Cassels

William R Brown

Daniel L Jarboe

Noelle Christine Vook

Elliott Jacob

William Vaughan

Ha Duong

Ramasubbu Jeyanthi

Thomas C Van Cott

Paul R Burnett

Jerald C Sadoff

Alan S Cross

Apurba K Bhattacharjee

Wendell David Zollinger

Ramasubbu Jevanthi

William M Vaughn

William M Vaugn

Walter K Franz

Edgar C Boedecker

Debrah L Birx

Ramassubbu Jeyanthi

Deborah L Birx

This invention relates to parenteral and mucosal vaccines against diseases caused by intercellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).

Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1&#x2013;100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.

'Burst-free' sustained release poly-(lactide/glycolide) microspheres

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.

Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix

A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophobic bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).

Sustained release hydrophobic bioactive PLGA microspheres

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group, and end-capped forms ranging in ratios from 100/0 to 1/99.

Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix

A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a non-steroidal, antiinflammatory drug over a duration from 24 hours to 2 months, comprising: a non-steroidal, antiinflammatory drug and a blend of biocompatible, biodegradable poly (lactide/glycolide).

Sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres

A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophocib bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).

Biodegradable pharmaceutical compositions and method for treating bacterial infections therein.

Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres

This invention relates to parenteral and mucosal vaccines against diseases aused by intracellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).

Vaccines against intracellular pathogens using antigens encapsulated

A hybrid evaporation-extraction process for preparing microspheres of a p(DL-lactide-to-glycolide) biodegradable polymer, comprising:

Extraction process for producing PLGA microspheres

Apparatus and methods for dispensing medicinals encapsulated in a biodegrble polymer in surgical and other wounds are described. The apparatus, a microcapsule drug applicator, allows the caregiver to implant or spread measured and uniform quantities of microencapsulated medicinals in or on surgical or traumatic wounds to prevent and/or treat infections. Specific examples where microencapsulated antibiotics may prove useful include, soft-tissue wounds, following debridement and reduction or fixation of open fractures, to osteomyelitic bone after surgical debridement, after surgical insertion of prostheses such as hip/knee replacements (arthroplasty), and following vascular surgery or grafting.

Microsphere drug application device

This invention is directed to oral parenteral and intestinal vaccines and eir use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

Growing community of inventors

Alpharetta, GA, United States of America

Jean A Setterstrom